CN100438876C - 20(s)-原人参二醇在制备抗抑郁药物中的应用 - Google Patents
20(s)-原人参二醇在制备抗抑郁药物中的应用 Download PDFInfo
- Publication number
- CN100438876C CN100438876C CNB2006100275071A CN200610027507A CN100438876C CN 100438876 C CN100438876 C CN 100438876C CN B2006100275071 A CNB2006100275071 A CN B2006100275071A CN 200610027507 A CN200610027507 A CN 200610027507A CN 100438876 C CN100438876 C CN 100438876C
- Authority
- CN
- China
- Prior art keywords
- protopanoxadiol
- animal
- medicine
- dosage
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000935 antidepressant agent Substances 0.000 title description 18
- 229940005513 antidepressants Drugs 0.000 title description 10
- 230000001430 anti-depressive effect Effects 0.000 title description 8
- 239000007924 injection Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 230000003001 depressive effect Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 description 59
- 238000012360 testing method Methods 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 32
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 230000037396 body weight Effects 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000581650 Ivesia Species 0.000 description 14
- 238000012449 Kunming mouse Methods 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 12
- 230000009182 swimming Effects 0.000 description 12
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 11
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 11
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 11
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229960002748 norepinephrine Drugs 0.000 description 11
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 11
- 229960003147 reserpine Drugs 0.000 description 11
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 11
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229960002464 fluoxetine Drugs 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000008354 sodium chloride injection Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 7
- 206010044565 Tremor Diseases 0.000 description 7
- 230000002547 anomalous effect Effects 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 229960004502 levodopa Drugs 0.000 description 7
- 206010025482 malaise Diseases 0.000 description 7
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- 208000004130 Blepharoptosis Diseases 0.000 description 5
- 206010015995 Eyelid ptosis Diseases 0.000 description 5
- 208000019022 Mood disease Diseases 0.000 description 5
- USSBBYRBOWZYSB-SCSAIBSYSA-N hydroxyaminovaline Chemical compound CC(C)[C@@H](N)C(=O)NO USSBBYRBOWZYSB-SCSAIBSYSA-N 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 201000003004 ptosis Diseases 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 208000017194 Affective disease Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000000891 anti-reserpine Effects 0.000 description 4
- 238000011095 buffer preparation Methods 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 230000037326 chronic stress Effects 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 3
- SFLSHLFXELFNJZ-CMIMLBRMSA-N 4-[(1r)-2-amino-1-hydroxy-1-tritioethyl]benzene-1,2-diol Chemical compound NC[C@@](O)([3H])C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-CMIMLBRMSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100427174 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-8 gene Proteins 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000035 biogenic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 150000002338 glycosides Chemical group 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229960002888 oxitriptan Drugs 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000272165 Charadriidae Species 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940087098 Oxidase inhibitor Drugs 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010042458 Suicidal ideation Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000010010 raising Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- -1 3,4-dihydroxy phenylamino Chemical group 0.000 description 1
- YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010050012 Bradyphrenia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- MDIGAZPGKJFIAH-UHFFFAOYSA-N Serotonin hydrochloride Chemical compound Cl.C1=C(O)C=C2C(CCN)=CNC2=C1 MDIGAZPGKJFIAH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940080383 levodopa 200 mg Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (2)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100275071A CN100438876C (zh) | 2006-06-09 | 2006-06-09 | 20(s)-原人参二醇在制备抗抑郁药物中的应用 |
US12/304,114 US8148354B2 (en) | 2006-06-09 | 2007-06-08 | Use of 20(S)-protopanaxadiol in manufacture of antidepressants |
EP07721389.0A EP2036566B1 (en) | 2006-06-09 | 2007-06-08 | Use of 20(s)-protopanoxadiol in manufacture of antidepressants |
KR1020097000335A KR101288172B1 (ko) | 2006-06-09 | 2007-06-08 | 항우울제 제조에서 20(s)-프로토파낙사다이올의 용도 |
PCT/CN2007/001816 WO2007143930A1 (fr) | 2006-06-09 | 2007-06-08 | Utilisation de 20(s)-protopanoxadiol dans la fabrication d'antidépresseurs |
JP2009513538A JP4993523B2 (ja) | 2006-06-09 | 2007-06-08 | 20(s)−プロトパナキサジオールの抗うつ薬製造への使用 |
US13/404,014 US20120214779A1 (en) | 2006-06-09 | 2012-02-24 | Application of 20(s)-protopanaxadiol in preparation of antidepressants |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100275071A CN100438876C (zh) | 2006-06-09 | 2006-06-09 | 20(s)-原人参二醇在制备抗抑郁药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1895256A CN1895256A (zh) | 2007-01-17 |
CN100438876C true CN100438876C (zh) | 2008-12-03 |
Family
ID=37607993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100275071A Active CN100438876C (zh) | 2006-06-09 | 2006-06-09 | 20(s)-原人参二醇在制备抗抑郁药物中的应用 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8148354B2 (zh) |
EP (1) | EP2036566B1 (zh) |
JP (1) | JP4993523B2 (zh) |
KR (1) | KR101288172B1 (zh) |
CN (1) | CN100438876C (zh) |
WO (1) | WO2007143930A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102125572A (zh) * | 2010-12-30 | 2011-07-20 | 黑龙江珍宝岛药业股份有限公司 | 一种药用组合物及其应用 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008155998A1 (ja) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | 抗不安抗うつ剤 |
WO2008155999A1 (ja) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | Gaba作動性ニューロン賦活剤 |
CN101612160B (zh) * | 2008-06-23 | 2011-08-31 | 上海药谷药业有限公司 | 化合物20(S)-人参皂苷Rh2在制备抗抑郁症药物中的应用 |
CN102145006A (zh) * | 2010-02-09 | 2011-08-10 | 张作光 | 人参皂甙Ppt的抗抑郁用途 |
CN101890040B (zh) * | 2010-07-27 | 2011-12-21 | 上海中药创新研究中心 | 一种具有抗疲劳作用的组合物及其应用 |
CN103211823B (zh) * | 2012-01-18 | 2014-11-05 | 上海中药创新研究中心 | 20(s)-原人参二醇衍生物及20(s)-原人参三醇衍生物在制备抗抑郁药物中的用途 |
CN102631322B (zh) * | 2012-04-23 | 2014-08-06 | 上海中医药大学 | 一种20(s)-原人参二醇干混悬剂及其制备方法 |
CN103961358B (zh) * | 2013-01-31 | 2016-07-06 | 上海中药创新研究中心 | 原人参二醇衍生物、原人参三醇衍生物在制药中的应用 |
CN103965281B (zh) | 2013-01-31 | 2016-06-08 | 上海中药创新研究中心 | 一种原人参二醇衍生物、其制备方法及其应用 |
CN103976957B (zh) * | 2013-02-08 | 2016-11-09 | 上海中医药大学 | 一种20(s)-原人参二醇微球及其制备方法和应用 |
KR101641509B1 (ko) * | 2015-01-22 | 2016-07-21 | 샘표 주식회사 | 아글리콘인 ppd 및/또는 ppt를 유효성분으로 포함하는 항스트레스용 조성물 |
CN111529539A (zh) * | 2020-04-29 | 2020-08-14 | 海南亚洲制药股份有限公司 | 一种原人参二醇在制备药物中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1763069A (zh) * | 2004-10-20 | 2006-04-26 | 吉林省中医中药研究院 | 人参皂苷Rg2的制备方法,其药物组合物及在制药中的应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1574806A (en) * | 1976-06-03 | 1980-09-10 | Inverni Della Beffa Spa | Production of purified ginseng extracts and pharmaceutical compositions containing the extracts |
US6083932A (en) * | 1997-04-18 | 2000-07-04 | Cv Technologies Inc. | Pharmaceutical compositions derived from ginseng and methods of treatment using same |
KR100448667B1 (ko) * | 2001-04-25 | 2004-09-13 | (주) 디지탈바이오텍 | 진세노사이드 가수분해물을 함유하는 퇴행성 뇌질환의예방 및 치료용 조성물 |
DE10158281A1 (de) * | 2001-11-19 | 2003-05-28 | Mediwirk Gmbh | Pharmazeutisches Präparat |
DE20119321U1 (de) * | 2001-11-19 | 2002-05-29 | Mediwirk Gmbh | Pharmazeutisches Präparat |
AU2002302997A1 (en) | 2002-05-16 | 2004-01-19 | Digital Biotech Co., Ltd. | Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides |
CN1251677C (zh) | 2002-10-22 | 2006-04-19 | 海南亚洲制药有限公司 | 一种以20(s)-原人参二醇为有效成分的抗癌辅助药物及应用 |
CN1526407A (zh) | 2003-01-06 | 2004-09-08 | 山东绿叶天然药物研究开发有限公司 | 抗肿瘤的原人参二醇注射剂及其制备方法 |
KR100688425B1 (ko) * | 2003-05-19 | 2007-03-02 | 홍림통산(주) | 유효 성분으로 진세노시드 Rh2를 함유하는 뇌세포 보호조성물 |
KR100555653B1 (ko) | 2003-10-09 | 2006-03-03 | 주식회사 진생사이언스 | 약효가 증강된 파낙스속 식물의 가공 추출물을 함유하는불안증세 예방 및 치료용 조성물 |
CN1252082C (zh) | 2004-04-29 | 2006-04-19 | 上海中药创新研究中心 | 原人参二醇及原人参三醇的制备方法 |
KR20060000488A (ko) * | 2004-06-29 | 2006-01-06 | 홍림통산(주) | 인삼 또는 홍삼 추출물, 그의 유산균 발효물 및 그의장내세균 발효물로 이루어진 군으로부터 선택된 1종이상의 인삼 추출물 소양증 예방 및 치료제 조성물 |
CN1615901A (zh) | 2004-09-21 | 2005-05-18 | 张平 | 一种含原人参二醇的药物组合物及其制备方法 |
US7884195B2 (en) | 2005-04-26 | 2011-02-08 | Long Yun Li | Method of extracting ginsengnoside Rg2m, pharmaceutical composition including ginsengnoside Rg2, and uses thereof |
CN1875975A (zh) | 2006-07-06 | 2006-12-13 | 复旦大学 | 人参奥克梯隆醇型皂苷元及其配糖体的应用 |
-
2006
- 2006-06-09 CN CNB2006100275071A patent/CN100438876C/zh active Active
-
2007
- 2007-06-08 KR KR1020097000335A patent/KR101288172B1/ko active IP Right Grant
- 2007-06-08 US US12/304,114 patent/US8148354B2/en active Active
- 2007-06-08 JP JP2009513538A patent/JP4993523B2/ja active Active
- 2007-06-08 EP EP07721389.0A patent/EP2036566B1/en active Active
- 2007-06-08 WO PCT/CN2007/001816 patent/WO2007143930A1/zh active Application Filing
-
2012
- 2012-02-24 US US13/404,014 patent/US20120214779A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1763069A (zh) * | 2004-10-20 | 2006-04-26 | 吉林省中医中药研究院 | 人参皂苷Rg2的制备方法,其药物组合物及在制药中的应用 |
Non-Patent Citations (2)
Title |
---|
西洋参二醇、三醇组皂甙对学生智力与情绪影响的实验研究. 周成林.沈阳体育学院学报,第3期. 1998 |
西洋参二醇、三醇组皂甙对学生智力与情绪影响的实验研究. 周成林.沈阳体育学院学报,第3期. 1998 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102125572A (zh) * | 2010-12-30 | 2011-07-20 | 黑龙江珍宝岛药业股份有限公司 | 一种药用组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2036566A4 (en) | 2011-06-15 |
US20120214779A1 (en) | 2012-08-23 |
KR101288172B1 (ko) | 2013-07-19 |
US8148354B2 (en) | 2012-04-03 |
JP4993523B2 (ja) | 2012-08-08 |
JP2009539780A (ja) | 2009-11-19 |
WO2007143930A1 (fr) | 2007-12-21 |
US20100234624A1 (en) | 2010-09-16 |
CN1895256A (zh) | 2007-01-17 |
KR20090029789A (ko) | 2009-03-23 |
EP2036566A1 (en) | 2009-03-18 |
EP2036566B1 (en) | 2013-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100438876C (zh) | 20(s)-原人参二醇在制备抗抑郁药物中的应用 | |
CN101347524B (zh) | 治疗抑郁症的中药组合物及其制备方法 | |
CN101987198B (zh) | 药物组合物 | |
CN102014931B (zh) | 芍药甙的抗抑郁症用途、制备方法及其药物组合物 | |
CN103980197B (zh) | 酸枣仁生物碱单体成分酸李碱及其制备方法与应用 | |
CN102283910B (zh) | 抗抑郁作用的中药组合物及其制剂和制备方法 | |
CN110585224A (zh) | 知母皂苷bⅰ、知母皂苷ⅰa、知母皂苷aⅲ在制备抗认知障碍疾病药物中的应用 | |
CN102775394B (zh) | 一种酰胺类化合物及其制备方法和应用 | |
CN108635352A (zh) | 木兰花碱在制备防治失眠症抑郁症药物的用途和制备方法 | |
CN101347562A (zh) | 抗抑郁药物及其制备方法与应用 | |
CN102716120B (zh) | (3r)-去-o-甲基毛狄泼老素在制备预防或治疗抑郁症的药物中的用途 | |
CN108498526A (zh) | 一种防治抑郁失眠疾病的药物组合物及其制备方法与应用 | |
CN101904894B (zh) | 独一味总苷在制备药物中的用途 | |
CN102824423B (zh) | 一种含白芍总苷和牛蒡苷的药物组合物及应用 | |
CN1850271B (zh) | 治疗神经衰弱或躯体形式障碍的药物组合物 | |
CN109528719B (zh) | 长春西汀在制备预防和/或治疗急进高原导致的高原病的药物中的应用 | |
CN108403980B (zh) | 一种降血糖植物提取物有效部位及其制备方法和应用 | |
CN105878258B (zh) | 类叶升麻苷在制备抗抑郁药物中的用途 | |
CN110279738A (zh) | 一种抗抑郁的亚精胺有效部位的提取方法及亚精胺有效部位提取物的用途 | |
CN1416880A (zh) | 四逆散及其活性部位的新用途 | |
CN110464730A (zh) | 大黄素甲醚-8-O-β-D-吡喃葡萄糖苷在防治抑郁症中的应用及相应药物 | |
CN102210692A (zh) | 伪酸枣仁苷元在制备抗抑郁症药物中的应用 | |
CN103054921A (zh) | 从北柴胡中提取的有效组分及其抗抑郁活性的应用 | |
CN100355424C (zh) | 治疗糖尿病的楤木提取物及楤木皂苷在制备治疗糖尿病的药物中的应用 | |
CN102138926A (zh) | 人参皂苷Rd在制备抗抑郁症药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUXI ZHONGHUI CHINESE MEDICINE CO., LTD. Free format text: FORMER OWNER: CHUANGXIN CHINESE MEDICINE RESEARCH CENTER, SHANGHAI Effective date: 20101223 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 BUILDING 1, NO.439, CHUNXIAO ROAD, HIGH TECHNOLOGY PARK, ZHANGJIANG, PUDONG NEW DISTRICT, SHANGHAI TO: 214101 NO.99, FURONG MIDDLE ROAD 3, ECONOMIC DEVELOPMENT ZONE, XISHAN, WUXI CITY, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101223 Address after: 214101 No. three, No. 99, Furong Road, Xishan Economic Development Zone, Jiangsu, Wuxi Patentee after: Wuxi Zhonghui Medicine Co.,Ltd. Address before: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Chunxiao Road No. 439 Building No. 1 Patentee before: SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE. |
|
ASS | Succession or assignment of patent right |
Owner name: CHUANGXIN CHINESE MEDICINE RESEARCH CENTER, SHANGH Free format text: FORMER OWNER: WUXI ZHONGHUI CHINESE MEDICINE CO., LTD. Effective date: 20130228 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214101 WUXI, JIANGSU PROVINCE TO: 201203 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130228 Address after: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Chunxiao Road No. 439 Building No. 1 Patentee after: SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE. Address before: 214101 No. three, No. 99, Furong Road, Xishan Economic Development Zone, Jiangsu, Wuxi Patentee before: Wuxi Zhonghui Medicine Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: WUXI ZHONGHUI CHINESE MEDICINE CO., LTD. Free format text: FORMER OWNER: CHUANGXIN CHINESE MEDICINE RESEARCH CENTER, SHANGHAI Effective date: 20141115 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 214101 WUXI, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141115 Address after: 214101 No. three, No. 99, Furong Road, Xishan Economic Development Zone, Jiangsu, Wuxi Patentee after: Wuxi Zhonghui Medicine Co.,Ltd. Address before: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Chunxiao Road No. 439 Building No. 1 Patentee before: SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200728 Address after: Room 310, 3rd floor, town living room, No. 999, Gaoxin East Road, Xinxiang City, Henan Province Patentee after: Xinxiang yiruida Pharmaceutical Technology Co.,Ltd. Address before: 214101 No. three, No. 99, Furong Road, Xishan Economic Development Zone, Jiangsu, Wuxi Patentee before: Wuxi Zhonghui Medicine Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221021 Address after: 214192 99 Xishan road three, Xishan Economic Development Zone, Wuxi, Jiangsu Patentee after: Wuxi Zhonghui Medicine Co.,Ltd. Address before: Room 310, 3rd floor, small town living room, 999 Gaoxin East Road, Xinxiang City, Henan Province Patentee before: Xinxiang yiruida Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221213 Address after: Room 118, building 20, no.1-42, Lane 83, Hongxiang North Road, Lingang New District, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 2013 13 Patentee after: Yiruida (Shanghai) Pharmaceutical Technology Co.,Ltd. Address before: 214192 99 Xishan road three, Xishan Economic Development Zone, Wuxi, Jiangsu Patentee before: Wuxi Zhonghui Medicine Co.,Ltd. |